Aperio Group LLC grew its stake in Amgen, Inc. (NASDAQ:AMGN) by 12.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 442,197 shares of the medical research company’s stock after purchasing an additional 50,291 shares during the quarter. Aperio Group LLC owned about 0.06% of Amgen worth $76,898,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Toronto Dominion Bank grew its position in shares of Amgen by 11.0% in the 3rd quarter. Toronto Dominion Bank now owns 279,280 shares of the medical research company’s stock worth $52,066,000 after buying an additional 27,726 shares during the period. Teacher Retirement System of Texas grew its position in Amgen by 16.5% during the 3rd quarter. Teacher Retirement System of Texas now owns 740,764 shares of the medical research company’s stock valued at $138,115,000 after purchasing an additional 104,871 shares during the last quarter. Putnam FL Investment Management Co. purchased a new stake in Amgen during the 3rd quarter valued at about $447,000. Wesbanco Bank Inc. grew its position in Amgen by 6.5% during the 2nd quarter. Wesbanco Bank Inc. now owns 106,792 shares of the medical research company’s stock valued at $18,393,000 after purchasing an additional 6,492 shares during the last quarter. Finally, Moody Lynn & Lieberson LLC purchased a new stake in Amgen during the 3rd quarter valued at about $2,353,000. Institutional investors and hedge funds own 79.53% of the company’s stock.
In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $189.75, for a total value of $289,368.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 4,575 shares of company stock valued at $838,064. 0.19% of the stock is currently owned by insiders.
Shares of Amgen stock traded down $3.86 on Friday, hitting $168.14. 3,678,821 shares of the company traded hands, compared to its average volume of 4,476,543. The stock has a market cap of $123,936.70, a P/E ratio of 13.37, a PEG ratio of 2.11 and a beta of 1.36. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17. Amgen, Inc. has a 52 week low of $152.16 and a 52 week high of $201.23.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.03 by ($0.14). The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The company’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.89 EPS. equities analysts expect that Amgen, Inc. will post 13.25 EPS for the current year.
Amgen declared that its board has authorized a share repurchase plan on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be issued a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.14%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 41.97%.
Several analysts recently commented on AMGN shares. Oppenheimer reissued a “buy” rating and set a $205.00 price objective on shares of Amgen in a research report on Tuesday, January 30th. Argus raised shares of Amgen from a “hold” rating to a “buy” rating and increased their price objective for the company from $192.33 to $220.00 in a research report on Tuesday, January 23rd. Piper Jaffray reissued a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Mizuho set a $192.00 price target on shares of Amgen and gave the company a “buy” rating in a report on Thursday, December 28th. Finally, Goldman Sachs downgraded shares of Amgen from a “conviction-buy” rating to a “buy” rating in a report on Friday, December 15th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $190.57.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/aperio-group-llc-has-76-90-million-holdings-in-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.